Pauline Camacho, MD
Endocrinology, Diabetes & Metabolism · Maywood, ILNPI 1730168816
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.3%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Amgen accounts for 97.2% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2020 at $10,000 and has fallen 98.3% since, to $167 in 2025.
Across 9 payments — averaging $1429.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$13K
- Novo Nordisk$175
- Eisai Inc.$125
- Mannkind Corporation$43
- Medtronic$22
Across 37 payments — averaging $705.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$23K
- Shire North American Group Inc$3K
What the payments were for
- Consulting fees$7,50058%
- Speaking & faculty fees$5,00039%
- Food & beverage$3233%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 5 | $12,500 |
| Novo Nordisk | 1 | $175 |
| Eisai Inc. | 1 | $125 |
| Mannkind Corporation | 1 | $43 |
| Medtronic | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,865 in reported general payments places this provider in the 85th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Teriparatide | 46 | $133,177 |
| OzempicSemaglutide | 87 | $90,445 |
| ForteoTeriparatide | 22 | $83,468 |
| TymlosAbaloparatide | 26 | $67,777 |
| TrulicityDulaglutide | 34 | $42,851 |
| JardianceEmpagliflozin | 29 | $42,783 |
| JanuviaSitagliptin Phosphate | 38 | $41,843 |
| SynthroidLevothyroxine Sodium | 248 | $26,570 |
| OmnitropeSomatropin | 34 | $25,539 |
| GenotropinSomatropin | 13 | $12,848 |
| Repatha SureclickEvolocumab | 11 | $9,836 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $6,699 |
| Cinacalcet Hcl | 39 | $6,399 |
| Humalog Kwikpen U-100Insulin Lispro | 16 | $6,269 |
| Calcitriol | 249 | $5,261 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $175 | $90,44587 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
Other endocrinology, diabetes & metabolism in Maywood
- Mary EmanueleMaywood$65K
- Wahid KassarChicago$884K
- Anthony PickLake Forest$665K
- Babak PazookiJoliet$582K
- Ammar BayrakdarEvergreen Park$517K
- George BakrisChicago$403K
- Terrence SwadeLombard$369K
- Wenyu HuangChicago$341K
- Liana BillingsSkokie$295K
- Daniel SoArlington Heights$283K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.